Russia’s Sputnik-V maker contacts DRAP to seek permission for emergency use of its vaccine in Pakistan
- The vaccine’s developers have said the shot has been found to be 91.4% effective in providing protection.
- Chinese firm Anhui Zheifi Longcom Biopharmaceuticals Company Limited has also applied for phase-III clinical trial of its vaccine in Pakistan.